This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

WCLC 2019

World Conference on Lung Cancer 2019

At the 2019 World Conference on Lung Cancer meeting, Boehringer Ingelheim hosted a symposium on treatment sequencing for advanced non-small cell lung cancer (NSCLC), and presented data highlighting recent findings in the treatment of lung cancer.

1 Symposium
8 Publications
8 Downloads
7-10 September 2019
Fira Gran Via, Barcelona, Spain

Publications

Publications on our emerging data were also presented at WCLC – please see downloads below.

Filter by:
Presentation Type
  • All presentation types
  • Oral Presentation
  • Poster Presentation
  • e-Presentation
Tumour Type
  • All tumour types
Sunday 8th September
Targeting NRG1-fusions in lung adenocarcinoma: afatinib as a novel potential treatment strategy
Author(s): Duruisseaux et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.14-25
Afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: combined analysis of two single-arm Phase IIIb studies
Author(s): De Marinis et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.14-62
Overall survival in pts with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: updated analysis of the GioTag study
Author(s): Hochmair et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P1.01-118
A Phase IIIb open-label study of afatinib in EGFR TKI-naïve patients with EGFRm+ NSCLC: Exploratory biomarker analysis
Author(s): Wang et al.
e-Presentation
Tumour Type(s): NSCLC
Abstract Number: EP1. 14-49
There are no publications which meet your criteria on this date
Monday 9th September
A Phase IIIb open-label study of afatinib* in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: Final analysis
Author(s): Wu et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P2.01-99
Afatinib in EGFR mutation-positive NSCLC: activity in patients with brain metastases, and impact on CNS progression/spread
Author(s): O’Byrne et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P2.14-60
Afatinib in EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: experience in ‘real-world’ clinical practice
Author(s): Brückl et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P2.01-79
A Phase IIIb, open-label study of afatinib in Caucasian EGFR TKI-naïve patients with EGFRm+ NSCLC: an interim analysis
Author(s): De Marinis et al.
Poster Presentation
Tumour Type(s): NSCLC
Presentation Number: P2.14-58
There are no publications which meet your criteria on this date

Find out more about other oncology events

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

© 2019 Boehringer Ingelheim International GmbH. All rights reserved.

Page last updated: September 2019